Cambridge Antibody Technology
Cambridge Antibody Technology (also known as CAT) is a biotechnology company based in the United Kingdom. It was established in 1989 and is renowned for its pioneering work in the field of antibody engineering, particularly in the development of monoclonal antibodies for therapeutic use.
History[edit | edit source]
Cambridge Antibody Technology was founded by Sir Gregory Winter, a British biochemist and Nobel laureate, and David Chiswell, a biotechnology entrepreneur. The company was established with the aim of commercialising the phage display technology developed by Winter at the MRC Laboratory of Molecular Biology in Cambridge.
Technology[edit | edit source]
The core technology of Cambridge Antibody Technology is the phage display of antibodies. This technology allows the generation of highly specific monoclonal antibodies for use in the treatment of various diseases. The company has developed a number of successful antibody-based drugs, including Humira (adalimumab), a treatment for rheumatoid arthritis and other autoimmune diseases, and Benlysta (belimumab), a treatment for systemic lupus erythematosus.
Acquisition[edit | edit source]
In 2006, Cambridge Antibody Technology was acquired by AstraZeneca, a multinational pharmaceutical and biopharmaceutical company. The acquisition allowed AstraZeneca to strengthen its biologics capabilities and expand its portfolio of antibody-based drugs.
Impact[edit | edit source]
The work of Cambridge Antibody Technology has had a significant impact on the field of biotechnology and medicine. The company's pioneering work in antibody engineering has led to the development of a new class of drugs that have transformed the treatment of a range of diseases, from cancer to autoimmune disorders.
See also[edit | edit source]
References[edit | edit source]
This <a href="UK">UK</a>-based <a href="Biotechnology">biotechnology</a> or <a href="pharmaceutical</a> company article is a stub.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
